Key result
Oral CoQ10 supports adjuvant therapy in CHF but lacks sufficient evidence for angina or hypertension.
Why the study?
The safety, efficacy, and dosing of Coenzyme Q10 in managing chronic heart failure, angina, and hypertension require clarification based on existing literature.
Does oral Coenzyme Q10 improve outcomes in adult patients with chronic heart failure, angina, and hypertension?
Does oral Coenzyme Q10 improve outcomes in adult patients with chronic heart failure, angina, and hypertension?
Coenzyme Q10 may be recommended as adjuvant therapy in selected patients with chronic heart failure, but evidence is insufficient to support its use in angina or hypertension, and it should not be used as monotherapy.
CoQ10 may merit consideration as adjuvant therapy in chronic HF; leaves open its role in angina or hypertension pending prospective trials.
PURPOSE: Coenzyme Q10 (CoQ10) has a pathophysiologic role in many disease states. The purpose of this review is to provide recommendations regarding the safety, efficacy, and dosing of CoQ10 in the management of chronic heart failure (CHF), angina, and hypertension. DATA SOURCES: Literature pertaining to the safety and efficacy of CoQ10 specifically in cardiovascular indications was reviewed. We used relevant clinical trials, articles, reviews, and letters that were selected from a literature search of the MEDLINE database (1974-2000), Micromedex Healthcare Series, and the Natural Medicines Comprehensive Database. FINDINGS: Coenzyme Q10 administered orally has favorable actions in the described cardiovascular conditions and appears to be safe and well tolerated in the adult population. Issues concerning optimum target dosages, potential interactions, monitoring parameters, and the role of CoQ10 as a monotherapeutic agent need to be investigated further. Favorable effects of CoQ10 on ejection fraction, exercise tolerance, cardiac output, and stroke volume are demonstrated in the literature; thus, the use of CoQ10 as adjuvant therapy in patients with CHF may be supported. CONCLUSIONS: Coenzyme Q10 therapy in angina and hypertension cannot be substantiated until additional clinical trials demonstrate consistent beneficial effects. However, CoQ10 may be recommended as adjuvant therapy in selected patients with CHE At this time, CoQ10 should not be recommended as monotherapy or first-line therapy in any disease state.
No takes yet. Share an insight, caveat, or question.
Tran et al. (2001) conducted a review in Chronic heart failure, angina, and hypertension. Coenzyme Q10 was evaluated. Oral Coenzyme Q10 demonstrated favorable effects on cardiac parameters supporting its use as adjuvant therapy in chronic heart failure, but lacks sufficient evidence for angina or hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: